Safety, immunogenicity, and clinical outcomes in patients with Morquio A syndrome participating in 2 sequential open-label studies of elosulfase alfa enzyme replacement therapy (MOR-002/MOR-100), representing 5 years of treatment
| Autor: | Hendriksz, Christian, Santra, Saikat, Jones, Simon A., Geberhiwot, Tarekegn, Jesaitis, Lynne, Long, Brian, Qi, Yulan, Hawley, Sara M., Decker, Celeste |
|---|---|
| Zdroj: | In Molecular Genetics and Metabolism April 2018 123(4):479-487 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect